Nicotinic Receptors and Schizophrenia
| Status: | Completed |
|---|---|
| Conditions: | Schizophrenia |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/21/2016 |
| Start Date: | January 2010 |
| End Date: | October 2014 |
The study determines if a new preparation of a drug designed to treat schizophrenia is more
slowly released into the body.
slowly released into the body.
3-2,4 dimethoxybenzylidene will be compounded with a methyallose compound in doses of 150
and 300 mg. The capsules will be administered singly and eventually bid to determine if
sustained blood levels comparable to steady state blood levels seen in previous studies can
be determined. Safety and EEG effects will be measured.
and 300 mg. The capsules will be administered singly and eventually bid to determine if
sustained blood levels comparable to steady state blood levels seen in previous studies can
be determined. Safety and EEG effects will be measured.
Inclusion Criteria:
- Healthy volunteers: males and females who are incapable of pregnancy
Exclusion Criteria:
- Medical illnesses requiring acute treatment
- History of seizures
- Substance abuse including nicotine
We found this trial at
1
site
Click here to add this to my saved trials
